<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01828736</url>
  </required_header>
  <id_info>
    <org_study_id>CVH-CT 02</org_study_id>
    <nct_id>NCT01828736</nct_id>
  </id_info>
  <brief_title>Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma</brief_title>
  <acronym>CVH-CT02</acronym>
  <official_title>Multicenter Randomized Phase 2 Trial of Gemcitabine - Platinum With or Without Trastuzumab in Advanced or Metastatic Urothelial Carcinoma With HER2 Overexpression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, Phase 2 trial to study the effectiveness and feasibility of
      association of trastuzumab with combination chemotherapy in advanced or metastatic bladder
      cancer patients. Combining monoclonal antibody therapy with combination chemotherapy may
      improve treatment efficacy on tumours overexpressed HER 2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 9, 2004</start_date>
  <completion_date type="Actual">February 23, 2010</completion_date>
  <primary_completion_date type="Actual">February 23, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free survival</measure>
    <time_frame>Participants will be followed from radomization until progression or death, up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Objective Response Rate will be assessed during treatment period, every 3 cycles, up to 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Participants will be followed all along the study period, an expected average of 3 years</time_frame>
    <description>Toxicity will be classify according to NCI-CTC criteria Version 2.0. Cardiac toxicity will be assessed according to the NYHA (New York Heart Association) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Quality of Life will be assessed during the study period, every 3 cycles (Arm A patients) or every 3 months (Arm B patients), up to 3 years</time_frame>
    <description>Quality of Life will be assessed according to the EORTC QLQ-C30 Version 3 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Participants will be followed from randomization until death or lost of follow-up, up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Recurrent Bladder Cancer</condition>
  <condition>Stage IV Bladder Cancer</condition>
  <condition>Transitional Cell Carcinoma of the Bladder</condition>
  <arm_group>
    <arm_group_label>Arm A: Platinum + Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV
+ If Creatinin Clearance &gt; 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance &lt; 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Platinum+Gemcitabine+Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab: Charging dose = 8mg/kg on day 1; then 6mg/kg every 21 days given IV + Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV
+ If Creatinin Clearance &gt; 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance &lt; 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV</description>
    <arm_group_label>Arm B: Platinum+Gemcitabine+Trastuzumab</arm_group_label>
    <other_name>anti-c-erB-2</other_name>
    <other_name>Herceptin</other_name>
    <other_name>MOAB HER2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days</description>
    <arm_group_label>Arm A: Platinum + Gemcitabine</arm_group_label>
    <arm_group_label>Arm B: Platinum+Gemcitabine+Trastuzumab</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>gemcitabin hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV: AUC 5 on Day 1 every 21 days</description>
    <arm_group_label>Arm A: Platinum + Gemcitabine</arm_group_label>
    <arm_group_label>Arm B: Platinum+Gemcitabine+Trastuzumab</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV, 70 mg/m² BSA on day 1 every 21 days</description>
    <arm_group_label>Arm A: Platinum + Gemcitabine</arm_group_label>
    <arm_group_label>Arm B: Platinum+Gemcitabine+Trastuzumab</arm_group_label>
    <other_name>cis-Diamminedichloroplatinum(II)</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Diamminodichloride, Platinum</other_name>
    <other_name>cis-Platinum</other_name>
    <other_name>cis Platinum</other_name>
    <other_name>Dichlorodiammineplatinum</other_name>
    <other_name>cis-Diamminedichloroplatinum</other_name>
    <other_name>cis Diamminedichloroplatinum</other_name>
    <other_name>cis-Dichlorodiammineplatinum(II)</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platidiam</other_name>
    <other_name>Platino</other_name>
    <other_name>NSC-119875</other_name>
    <other_name>Biocisplatinum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Transitional cell carcinoma of the urothelium or bladder histologically proven stage
             IV AJCC [locally advanced (T4b and / or N + M0) unresectable or metastatic (M1)]

          -  Tumor and / or metastasis overexpressing HER2 immunohistochemistry (IHC 3 +) or IHC 2
             + and FISH +. Centralized analysis.

          -  Measurable disease with at least one lesion with a diameter&gt; 2 cm for conventional
             methods (clinical examination, CT or MRI) or&gt; 1 cm for the helical scanner. In case of
             single metastasis, metastatic disease should be histologically proven

          -  Age ≥ 18 years and ≤80 years

          -  Life expectancy&gt; 3 months,

          -  Index performance status &lt;2 according to ECOG PS,

          -  No prior chemotherapy other than adjuvant and / or neoadjuvant chemotherapy, without
             Herceptin ® and complete for more than 6 months (naive to any previous chemotherapy in
             the metastatic setting)

          -  No radiotherapy within 4 weeks prior to inclusion,

          -  Normal cardiac function as measured by ejection fraction (LVEF&gt; 50%),

          -  Blood and liver satisfactory constants:

        Hematological criteria: - Neutrophils&gt; 1.5 x 109 / L, - Chips&gt; 100 x 109 / L - Hemoglobin&gt;
        10 g / dL, Liver function: - Alkaline phosphatase (unless bone metastases) &lt;2 x N - Total
        bilirubin &lt;1.5 x N - transaminases (AST, ALT) &lt;1.5 x N, renal Constants: - Creatinine
        clearance &gt; 30 ml / min (Cockcroft and Gault, cf. Annex XV protocol)

        - Patient's written consent after full information.

        Exclusion Criteria:

          -  Concurrent treatment with an experimental drug, participation in another clinical
             trial within &lt;30 days

          -  Patients previously treated with Herceptin ®, or another treatment targeting growth
             factors EGF (eg Iressa ®, Tarceva ®)

          -  Existence of a severe pulmonary disease, liver or kidney is likely to be exacerbated
             by the treatment,

          -  Other medical conditions: congestive heart failure or angina pectoris even if
             medically controlled failure, history of myocardial infarction before entering the
             trial, hypertension or uncontrolled arrhythmias, significant valvular disease,

          -  Patient with dyspnoea at rest or requiring oxygen therapy or with respiratory failure,

          -  Presence of a severe infection requiring antibiotics,

          -  Presence of CNS metastases or meningeal

          -  History of another malignancy uncured or cured for less than 5 years (except basal
             cell carcinoma, papillary thyroid carcinoma in situ of the cervix treated)

          -  Pregnant or lactating or not using effective contraception Women,

          -  For Cisplatin only: carrying a serious neurological disease, current events devices&gt;
             NCI grade 2 neuropathy, hearing loss, creatinine clearance &lt;60 ml / min, the patient
             can not support a patient hydration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane Oudard, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges Pompidou, Paris (France)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Beuzeboc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Curie Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques saint Luc - Université Catholique de Louvain</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental de la Vendée</name>
      <address>
        <city>La Roche-sur-yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Hartmann</name>
      <address>
        <city>Neuilly-Sur-Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curie Institute</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Saint Joseph Paris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2013</study_first_submitted>
  <study_first_submitted_qc>April 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2013</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urothelial carcinoma</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

